Today’s TraderNotes include: TapImmune Inc. (OTCBB: TPIM), RXi Pharmaceuticals Corp. (Nasdaq: RXII), Vion Pharmaceuticals Inc. (Nasdaq: VION), Neuralstem Inc. (AMEX: CUR), Amgen Inc. (Nasdaq: AMGN), Gilead Sciences Inc. (Nasdaq: GILD), Biogen Idec Inc. (Nasdaq: BIIB) and Genaera Corp. (Nasdaq: GENR)
“TapImmune Inc. (TPIM) shares climbed nearly 39 percent to 43 cents in Monday’s mid-morning trading, following news that an article in the Journal of Investigative Dermatology confirmed the company’s TAP (Transporters Associated with Antigen Processing) vaccine should be considered as a candidate for the treatment of Melanoma.
“The company's lead product, the TAP vaccine, performs a key step in moving characteristic cancer markers, known as antigens, to the surface of cells. Without TAP, there are no cancer markers and the body's immune system fails to detect and eradicate cancerous cells.”
“RXi Pharmaceuticals Corp. (RXII) shares continued last week’s slide down the charts Monday morning, falling nearly 4 percent to $9.50. RXi, a discovery-stage biopharmaceutical company, focuses on developing and commercializing proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases.
“The company intends to identify lead compounds and advance toward preclinical and clinical development programs in the various therapeutic areas, including neurology; metabolic diseases, such as obesity and obesity-related Type 2 diabetes; and oncology.”
Investors can view all of the TraderNotes and investment articles for free by visiting:
http://www.beaconequity.com/m
Join the fastest growing investor community at:
http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of TapImmune Inc. (OTCBB: TPIM). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research (“Beacon”) certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon Equity Research and its affiliates have been compensated forty seven thousand five hundred dollars from non-controlling third party (StocksJournal) for the enrollment of TPIM in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
